Createrna ：MY008211 agranted marketing approval through priority review and approval procedure.

On June 11, the NMPA official website showed that the first innovative drug from Langlai Technology, Lanocopan Hydrochloride Tablets, was granted marketing approval through the priority review and approval procedure for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitor therapy.

Lanocopan Hydrochloride Tablets (development code: MY008211A) are a CFB inhibitor discovered and developed by Langlai Technology. In vitro mechanistic studies have shown that MY008211A can bind to CFB, effectively inhibiting complement pathway activation, thereby suppressing hemolysis.

Buy MY008211A from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.